ZeaVision expands distribution of its EyePromise supplement line
CHESTERFIELD, Mo. — ZeaVision on Wednesday announced that its EyePromise natural supplements are now available for broader distribution through vitamin, health retail and e-tail channels.
EyePromise products contain the highest levels of natural zeaxanthin of any eye health supplement, according to ZeaVision. The newest formula, EyePromise vizual EDGE, is based on the success of EyePromise vizual EDGE PRO, popular among professional athletes because it enhances their ability to see objects better and, therefore, react faster.
"With more than 40 million doses consumed, thousands of consumers and professional athletes have already experienced the benefits, so this is the next natural step in our evolution,” stated Dennis Gierhart, ZeaVision founder. “We’ve developed a line of nutraceuticals with the optimal combination of natural ingredients to deliver on our mission to improve and preserve healthy vision.”
ZeaVison cited research that demonstrated that consuming the optimal amount of zeaxanthin (found naturally in the center of the eye) builds the density of macular pigment. Zeaxanthin is scarce in most diets and only supplementation can deliver enough to build the macula, ZeaVision suggested. A daily dosage of zeaxanthin enhances vision in a variety of ways related to color saturation, contrast, glare and light sensitivity that can improve eye function.
C&D to expand manufacturing capacity of gummy vitamins by 75%
EWING, N.J. — Church & Dwight on Thursday announced plans to expand its gummy vitamin production capacity through the addition of a new production line to be constructed at its manufacturing facility in Pennsylvania. The company will continue to manufacture gummy vitamins at its two facilities in Washington.
Construction will begin in January 2014 and the line is scheduled to be operational in the first quarter of 2015.
“The gummy vitamin business is strategically important to Church & Dwight and is expected to be a significant contributor to the future growth of sales, earnings and cash flows,” James Craigie, chairman and CEO said. “Our gummy vitamin sales are growing at a 20% rate to approximately $300 million in annual net sales in 2013. We expect double-digit gummy vitamin sales growth in 2014," he said. "We believe the future prospects of the gummy vitamin category are strong as more adults switch from traditional vitamin pills to gummy vitamins. This investment will expand our production capacity by 75% and will help to drive our long-term goals for revenue and earnings growth.”
Church & Dwight expects to invest approximately $55 million in capital expenditures to construct the new production line, which is expected to employ approximately 180 people. As announced today by the Commonwealth of Pennsylvania, the company has received an economic development assistance package from the Commonwealth in connection with the investment, consisting of grants, tax credits and training funds.
Crossix Solutions offers new analytics tool to measure success of point-of-care campaigns
NEW YORK — Crossix Solutions on Tuesday introduced its latest analytics innovation, Crossix POC Impact, which enables marketers to go beyond prescriber data and capture patient impact for a true representation of campaign effectiveness for the point-of-care marketing channel.
"POC campaigns have the power to influence patient conversion and adherence, which makes accurate measurement crucial," said Asaf Evenhaim, CEO Crossix. "Our patient-centered solution is a breakthrough in marketing analytics and for the first time empowers POC marketers and brand managers to accurately determine ROI, by capturing critical data missed by other methods that estimate impact based on physician prescribing behavior alone."
Crossix POC Impact also allows healthcare marketers to measure incremental purchases of prescription and over-the-counter medications, at both the individual and household level; specific tactics within POC programs, such as in-office TV, wallboards, patient brochures and co-pay offer distribution; impact of campaigns in concert with non-POC initiatives; and performance of pharmacy marketing programs.
"Crossix’s patient-centric campaign analytics are a valuable addition to the measurement tool-kit at the point-of-care," said Dan Stone, co-chair of the Point of Care Communication Council (PoC3) and CEO of AccentHealth, a point-of-care TV network. "With the Crossix methodology, a campaign¹s impact can be measured versus other POC tactics and relative to other direct-to-consumer channels."
"Traditional measurement approaches have undervalued the true impact of the POC channel," said Tom McGuinness, co-chair of PoC3 and CEO of PatientPoint, a provider of patient and physician engagement solutions at the point of care. "This patient-focused approach helps our clients understand the full impact of their campaigns, and expands beyond Rx implications to measure campaigns more broadly, from an OTC and CPG perspective."
Crossix POC Impact is part of the company’s suite of privacy-safe campaign analytics and optimization solutions and uses a consistent methodology that enables comparisons across tactics and channels within the broader DTC marketing mix. More than a dozen marketing agencies and pharmaceutical companies have captured revealing campaign analytics with the new solution, Crossix noted.